Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma. [electronic resource]
Producer: 20190903Description: 958-967 p. digitalISSN:- 1556-1380
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- administration & dosage
- Brain Neoplasms -- immunology
- Calgranulin B -- metabolism
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- ErbB Receptors -- genetics
- Erlotinib Hydrochloride -- administration & dosage
- Female
- Follow-Up Studies
- Gefitinib -- pharmacology
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Myeloid-Derived Suppressor Cells -- drug effects
- Prognosis
- Survival Rate
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.